D.E. Shaw & Co’s Translational Development Acquisition Corp Units TDACU Stock Holding History

D.E. Shaw & Co’s Portfolio TDACU Stock Details TDACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-350,000	Closed	-$3.69M	–	5314
2026 Q1	$3.69M	Hold	350,000	–	–	﹤0.01%	2402
2025 Q4	$3.69M	Hold	350,000	–	–	﹤0.01%	2563
2025 Q3	$3.64M	Hold	350,000	–	–	﹤0.01%	2491
2025 Q2	$3.6M	Hold	350,000	–	–	﹤0.01%	2278
2025 Q1	$3.55M	Hold	350,000	–	–	﹤0.01%	2159
2024 Q4	$3.51M	Buy	+350,000	New	+$3.51M	﹤0.01%	2270

Other funds holding TDACU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

D.E. Shaw & Co's TDACU Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Translational Development Acquisition Corp Units (TDACU) in Q2 2026, closing a stake of 350,000 shares — an estimated $3.69M sold.

D.E. Shaw & Co first reported a position in TDACU in Q4 2024 and held it in 6 quarters. The position peaked at $3.69M in Q1 2026. 3 funds tracked by Wall St. Rank hold TDACU as of Q2 2026.

D.E. Shaw & Co reported no remaining Translational Development Acquisition Corp Units position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 350,000 Translational Development Acquisition Corp Units shares in Q2 2026, an estimated $3.69M.
D.E. Shaw & Co first reported a position in Translational Development Acquisition Corp Units in Q4 2024 and held it in 6 quarters.
D.E. Shaw & Co's Translational Development Acquisition Corp Units position peaked at $3.69M in Q1 2026.
3 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Units as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.